Definigen Closes $3.8M Series A Round | GenomeWeb

NEW YORK (GenomeWeb News) – Cambridge, UK-based Definigen said today that it has raised a total of £2.3 million ($3.8 million) in a Series A round of funding.

The stem cell products firm said that it closed the round after the most recent investment of £1 million led by Cambridge Enterprise and 24 Haymarket, with additional participation from existing investors Abcam, Providence Investment Company, Cambridge Capital Group, and Jonathan Milner. New investors in the round included LBA, Wren Capital, and Ranworth Capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.